Altimmune (ALT) Common Equity (2010 - 2026)

Altimmune (ALT) has 17 years of Common Equity data on file, last reported at $284.0 million in Q1 2026.

• Common Equity for Q1 2026 came in at $284.0 million, up 99.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $284.0 million (up 99.76% YoY), and the FY2025 annual result was $224.9 million, up 82.09% from the prior year.
• Common Equity climbed to $284.0 million in Q1 2026 per ALT's latest filing, from $224.9 million in the prior quarter.
• Over five years, Common Equity peaked at $284.0 million in Q1 2026 and troughed at $123.5 million in Q4 2024.
• A 5-year average of $178.2 million and a median of $172.9 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2026: Common Equity plunged 36.37% in 2024, then surged 99.76% in 2026.
• A 5-year view of Common Equity shows it stood at $185.3 million in 2022, then grew by 4.75% to $194.1 million in 2023, then sank by 36.37% to $123.5 million in 2024, then surged by 82.09% to $224.9 million in 2025, then rose by 26.28% to $284.0 million in 2026.
• Business Quant data shows ALT's Common Equity at $284.0 million in Q1 2026, $224.9 million in Q4 2025, and $185.6 million in Q3 2025.